Ogura M - Search Results

1

Addition of docetaxel to S-1 without platinum prolongs survival of patients with advanced gastric cancer: a randomized study (START).

Koizumi W, Kim YH, Fujii M, Kim HK, Imamura H, Lee KH, Hara T, Chung HC, Satoh T, Cho JY, Hosaka H, Tsuji A, Takagane A, Inokuchi M, Tanabe K, Okuno T, Ogura M, Yoshida K, Takeuchi M, Nakajima T; JACCRO and KCSG Study Group. Koizumi W, et al. Among authors: ogura m. J Cancer Res Clin Oncol. 2014 Feb;140(2):319-28. doi: 10.1007/s00432-013-1563-5. Epub 2013 Dec 24. J Cancer Res Clin Oncol. 2014. PMID: 24366758 Free PMC article. Clinical Trial.

2

[Retrospective analysis of FOLFOX4 neurotoxicity for recovery from advanced colorectal cancer].

Matsuda M, Matsusaka S, Kuboki Y, Itimura T, Ogura M, Suenaga M, Syouji D, Watanabe C, Chin K, Mizunuma N, Hatake K. Matsuda M, et al. Among authors: ogura m. Gan To Kagaku Ryoho. 2008 Mar;35(3):461-6. Gan To Kagaku Ryoho. 2008. PMID: 18347395 Japanese.

3

[Safety and efficacy analysis of FOLFOX4 regimen in elderly compared to younger colorectal cancer patients].

Kuboki Y, Ichimura T, Ogura M, Matsuda M, Suenaga M, Shinozaki E, Matsuzaka S, Chin K, Mizunuma N, Hatake K. Kuboki Y, et al. Among authors: ogura m. Gan To Kagaku Ryoho. 2008 May;35(5):781-5. Gan To Kagaku Ryoho. 2008. PMID: 18487913 Japanese.

4

Management of venous thromboembolism in colorectal cancer patients treated with bevacizumab.

Suenaga M, Mizunuma N, Kobayashi K, Shinozaki E, Matsusaka S, Chin K, Kuboki Y, Ichimura T, Ozaka M, Ogura M, Fujiwara Y, Matsueda K, Konishi F, Hatake K. Suenaga M, et al. Among authors: ogura m. Med Oncol. 2010 Sep;27(3):807-14. doi: 10.1007/s12032-009-9289-6. Epub 2009 Aug 21. Med Oncol. 2010. PMID: 19697164 Clinical Trial.

5

Circulating tumor cells as a surrogate marker for determining response to chemotherapy in patients with advanced gastric cancer.

Matsusaka S, Chìn K, Ogura M, Suenaga M, Shinozaki E, Mishima Y, Terui Y, Mizunuma N, Hatake K. Matsusaka S, et al. Among authors: ogura m. Cancer Sci. 2010 Apr;101(4):1067-71. doi: 10.1111/j.1349-7006.2010.01492.x. Epub 2010 Jan 12. Cancer Sci. 2010. PMID: 20219073 Free article.

6

[The incidence of gastrointestinal bleeding, thromboembolic events, and gastrointestinal perforation in metastatic or unresectable gastric cancer during chemotherapy].

Ichimura T, Chin K, Kobayashi K, Osaka M, Kuboki Y, Ogura M, Shinozaki E, Suenaga M, Matsuzaka S, Mizunuma N, Hatake K. Ichimura T, et al. Among authors: ogura m. Gan To Kagaku Ryoho. 2010 Nov;37(11):2131-6. Gan To Kagaku Ryoho. 2010. PMID: 21084812 Japanese.

7

Irinotecan monotherapy offers advantage over combination therapy with irinotecan plus cisplatin in second-line setting for treatment of advanced gastric cancer following failure of fluoropyrimidine-based regimens.

Oba M, Chin K, Kawazoe Y, Takagi K, Ogura M, Shinozaki E, Suenaga M, Matsusaka S, Mizunuma N, Hatake K. Oba M, et al. Among authors: ogura m. Oncol Lett. 2011 Mar;2(2):241-245. doi: 10.3892/ol.2011.242. Epub 2011 Jan 20. Oncol Lett. 2011. PMID: 22866071 Free PMC article.

8

Availability of irinotecan in a second-line setting confers survival benefit to patients with advanced gastric cancer refractory to fluoropyrimidine-based regimens.

Oba M, Chin K, Kawazoe Y, Takagi K, Ogura M, Shinozaki E, Suenaga M, Matsusaka S, Mizunuma N, Hatake K. Oba M, et al. Among authors: ogura m. Oncol Lett. 2011 Mar;2(2):247-251. doi: 10.3892/ol.2011.241. Epub 2011 Jan 20. Oncol Lett. 2011. PMID: 22866072 Free PMC article.

9

Grade 3/4 neutropenia is a limiting factor in second-line FOLFIRI following FOLFOX4 failure in elderly patients with metastatic colorectal cancer.

Kuboki Y, Mizunuma N, Ozaka M, Ogura M, Suenaga M, Shinozaki E, Matsusaka S, Chin K, Matsuura M, Hatake K. Kuboki Y, et al. Among authors: ogura m. Oncol Lett. 2011 May;2(3):493-498. doi: 10.3892/ol.2011.260. Epub 2011 Feb 28. Oncol Lett. 2011. PMID: 22866109 Free PMC article.

10

Anticoagulant therapy for venous thromboembolism detected by Doppler ultrasound in patients with metastatic colorectal cancer receiving bevacizumab.

Suenaga M, Mizunuma N, Shinozaki E, Matsusaka S, Ozaka M, Ogura M, Chin K, Yamaguchi T. Suenaga M, et al. Among authors: ogura m. Onco Targets Ther. 2015 Jan 27;8:243-9. doi: 10.2147/OTT.S75722. eCollection 2015. Onco Targets Ther. 2015. PMID: 25670906 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

1,225 results

Search Page